9.75
+0.06(+0.62%)
Currency In USD
Address
500 Unicorn Park Drive
Woburn, MA 01801
United States of America
Phone
781 222 9600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
479
First IPO Date
July 20, 2018
| Name | Title | Pay | Year Born |
| Dr. Sushil Patel Ph.D. | Chief Executive Officer & Director | 665,050 | 1971 |
| Ms. Emily Luisa Hill | Chief Financial Officer | 593,047 | 1980 |
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer | 668,686 | 1967 |
| Mr. Philip Astley-Sparke F.S.A. | Executive Chairman | 960,520 | 1971 |
| Ms. Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management | 0 | N/A |
| Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | 0 | N/A |
| Mr. Camilo Garcia M.A., M.B.A. | Chief Human Resource Officer | 0 | N/A |
| Mr. Shawn Glidden J.D. | Senior Vice President of General Counsel | 0 | N/A |
| Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer | 0 | 1976 |
| Mr. Christopher Sarchi | Chief Commercial Officer | 0 | 1969 |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.